SCHEMBL6336997

SCHEMBL6336997

COC(=O)c1ccccc1NC(=O)c1ccc(Oc2ccc3cc(OCc4ccccc4)ccc3c2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.66
KDM4E B2RXH2 6/20 0.66
HPGD P15428 4/20 0.66
ALDH1A1 P00352 3/20 0.66
NPC1 O15118 4/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
RAB9A P51151 3/20 0.56
CASP3 P42574 1/20 0.56
TAAR1 Q96RJ0 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
TSHR P16473 3/20 0.54
CYP1A2 P05177 3/20 0.54
CYP2C19 P33261 3/20 0.54
CYP2D6 P10635 1/20 0.54
ELANE P08246 1/20 0.54
PRTN3 P24158 1/20 0.54
HSD17B10 Q99714 3/20 0.53
LMNA P02545 3/20 0.52
NPSR1 Q6W5P4 1/20 0.52
POLB P06746 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6338190 0.92 KDM4E (0.66) MAPTKDM4EHPGDALDH1A1NPC1
SCHEMBL2291513 0.89 KDM4E (0.69) MAPTKDM4EHPGDALDH1A1NPC1
SCHEMBL6410492 0.88 TSHR (0.62) MAPTKDM4EHPGDALDH1A1NPC1
SCHEMBL6340720 0.86 ALDH1A1 (0.52) MAPTKDM4EHPGDALDH1A1SMN1; SMN2
SCHEMBL6339040 0.85 ELANE (0.62) MAPTKDM4EHPGDALDH1A1NPC1
SCHEMBL2277733 0.84 KDM4E (0.64) MAPTKDM4EHPGDALDH1A1NPC1
SCHEMBL7710629 0.83 KDM4E (0.66) MAPTKDM4EHPGDALDH1A1NPC1
SCHEMBL22213599 0.83 MEN1 (0.57) MAPTKDM4EHPGDALDH1A1NPC1
SCHEMBL22213622 0.83 KDM4E (0.57) MAPTKDM4EHPGDALDH1A1NPC1
SCHEMBL2291530 0.81 KDM4E (0.69) MAPTKDM4EHPGDALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1245380-C Anthranilic acid derivatives TEIJIN LTD (JP) 2006-03-15 CN disclosed
US-6890932-B2 Immunoglobulin e antibody suppressors TEIJIN LIMITED (JP) 2005-05-10 US disclosed
EP-1101755-B1 ANTHRANILIC ACID DERIVATIVES TEIJIN LTD (JP) 2004-10-06 EP disclosed
US-20030232811-A1 Immunoglobulin e antibody suppressors TEIJIN LIMITED 2003-12-18 US disclosed
US-6649656-B1 Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents TEIJIN LIMITED (JP) 2003-11-18 US disclosed
EP-1101755-A1 ANTHRANILIC ACID DERIVATIVES TEIJIN LIMITED (JP) 2001-05-23 EP disclosed
CN-1048239-C Naphthalene deriv. TEIJIN LTD (JP) 2000-01-12 CN disclosed
CN-1153511-A Naphthalene deriv. TEIJIN LTD (JP) 1997-07-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232811-A1 Immunoglobulin e antibody suppressors IGLV6-57, FCGRT, IGSF11 MAPT 2538/4885KDM4E 875/4885HPGD 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.